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Abstract
Background: PET/CT with F-18-fluorodeoxyglucose (FDG) images of patients suffering from metastatic melanoma
have been analysed using fractal and multifractal analysis to assess the impact of monoclonal antibody
ipilimumab treatment with respect to therapy outcome.
Results: Thirty-one cases of patients suffering from metastatic melanoma have been scanned before and after
two and after four cycles of treatment. For each patient, we calculated the fractal and multifractal dimensions using
the box-counting method on the digitalised PET/CT images of all three studies to assess the therapeutic
outcome. We modelled the spreading of malignant cells in the body via kinetic Monte Carlo simulations to address the
dynamical evolution of the metastatic process and to predict the spatial distribution of malignant lesions. Our
analysis shows that the fractal dimensions which describe the tracer dispersion in the body decrease consistently
with the deterioration of the patient’s therapeutic outcome condition. In 20 out of 24 cases, the fractal
analysis results match those of the treatment outcome as defined by the oncologists, while 7 cases are
considered as special cases because the patients had non-tumour-related findings or side effects which affect
the results. The decrease in the fractal dimensions with the deterioration of the patient conditions (in terms
of disease progression) is attributed to the hierarchical localisation of the tracer which accumulates in the
affected lesions and does not spread homogeneously throughout the body. Fractality emerges as a result of
the migration patterns which the malignant cells follow for propagating within the body (circulatory system,
lymphatic system). Analysis of the multifractal spectrum complements and supports the results of the fractal
analysis. In the kinetic Monte Carlo modelling of the metastatic process, a small number of malignant cells
diffuse through a fractal medium representing the blood circulatory network. Along their way, the malignant
cells engender random metastases (colonies) with a small probability and, as a result, fractal spatial distributions of the
metastases are formed similar to the ones observed in the PET/CT images.
Conclusions: The Monte Carlo-generated spatial distribution of metastases changes with time approaching values
close to the ones recorded in the metastatic patients. Thus, we propose that fractal and multifractal analyses have
potential applications in quantification of the evaluation of PET/CT images to monitor the disease evolution as
well as the response to different medical treatments. The proposed approach, being operator independent, can
offer new diagnostic tools in parallel to the visual location of the lesions and may improve multiparameter
assessment of FDG PET/CT studies.
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Background
Many constituent networks of the human body present
complicated geometric structures which derive from
their functional needs, i.e. the geometry of the network
serves its functionality. Common examples are (a) the
circulatory system which is responsible for the efficient
distribution of blood in the body, (b) the respiratory sys-
tem which coordinates the transport of oxygen in the
body and the collection and release of carbon dioxide
and (c) the nervous system which controls the dynamic
transmission of information via electrical signals in the
brain and throughout the body [1]. These three major
systems are complex structures with branching and sub-
branching down in many hierarchical orders. Branching
is considered as a very efficient and energy-saving archi-
tecture to transfer matter (or information) from a cen-
tral source (organ) to a large number of destinations.
Because of branching, the body systems are self-similar
in many orders of magnitude and exhibit fractal scaling.
In particular, the blood circulatory system distributes
the blood in the whole body starting from an organ of
large size and reaching individual cells. To achieve this,
the distribution network starts from a large artery leav-
ing the heart and branches out in many levels. At each
level, the number of branches increases while their
diameter decreases in order to reach and feed all cells.
This is a mathematical property of fractals in 3D which
are constructed as space filling objects [2].
There have been a large number of attempts to quan-
tify the value of the fractal dimensions of the cardiovas-
cular system. Already in 1977, Mandelbrot predicted
that the fractal dimension of an arterial tree should be
smaller than 3 and he coined the value 2.7 as plausible
in refs [2, 3]. Huang et al. measured experimentally a
value df = 2.71 for pulmonary arteries and df = 2.69 for
pulmonary veins [4]. Helmberger et al. reported fractal
dimensions of the lung vessels in pulmonary hyperten-
sion patients as df = 2.34, with df increasing to the value
2.37 for patients without pulmonary hypertension [5].
Gil-García et al. showed experimentally that the arterial
pattern of the dog kidneys has fractal dimension ~2.7 [6].
The blood circulatory system often serves as a means
of transportation for malignant cells to migrate through
the body. As stem cancer cells migrate, they colonize
distant areas producing metastases, which are the most
frequent causes of death for patients with cancer. The
molecular mechanisms of metastasis are still not well
understood due to their biological complexity, but the
migration through the blood circulatory system seems
plausible since all body cells come in direct contact and
exchange with blood [7]. With this scenario the pattern
of migration and colonization of malignant cells should
be directly linked with the structure of the distributing
blood network. It is then reasonable to search for
fractality in the distribution of metastases in the human
body, since the transportation network distributing the
cancer cells is fractal. In many cases, the evolution of
cancer (melanoma in this case) can take a long time
and it is a dynamical process. The final distribution is
achieved only at the latest stages, while fractality
changes during the various stages of the disease, as the
spatial distribution of metastatic structures expands in
the body.
One molecular imaging technique for the detection
of primary tumours and metastases is positron emission
tomography (PET) using the radioactive biomarker F-
18-fluorodeoxyglucose (FDG). This technique allows
the detection of viable tumour tissue and is used for
staging and therapy monitoring of melanoma patients
since several years [8–13]. In particular, the use of hy-
brid systems, like PET/CT and PET/MRI, allows a bet-
ter anatomic allocation of the PET findings and leads to
an improvement of both diagnosis and treatment plan-
ning [14].
Metastatic melanoma had a poor diagnosis with a me-
dian overall survival of less than 1 year, until recently
[15]. The conventional treatment consisted in chemo-
therapy, radiotherapy, high-dose interleukin-2 and best
supportive care. An improvement of the overall survival
was achieved after the discovery of ipilimumab [15, 16].
Ipilimumab is a fully human, recombinant monoclonal
antibody that activates the immune system by targeting
cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4).
CTLA-4 is a type 1 transmembrane glycoprotein whose
expression is primarily restricted to T cells [17]. It is a
key negative regulator of T lymphocyte activation via
antagonism of CD28-mediated co-stimulation. Melan-
oma, and tumours in general, can take advantage of this
inhibitory mechanism used by the immune system to
reduce T cell response. Therefore, the use of blocking
antibodies against this inhibitory checkpoint, like ipili-
mumab, can enhance anti-tumour response.
Bearing these in mind, it is reasonable to use fractal
and multifractal analysis as a quantification procedure
for the evaluation of FDG images to monitor the disease
evolution as well as the patient’s response to different
medical treatments [2, 18, 19]. In the current study, we
demonstrate the use of fractal/multifractal analysis in
detecting the response of 31 melanoma patients to treat-
ment with ipilimumab monoclonal antibody, as will be
explained in the sequel. The proposed analysis has the
advantage of being operator independent and it offers
new diagnostic directions, in parallel to the more labori-
ous approaches of visually locating or manually contour-
ing lesions in images [8].
In the next section, we describe the properties of the
patients group and the fractal and multifractal methods
used in the analysis of the spatial distribution of the
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metastatic lesions. We also present the Kinetic Monte
Carlo (KMC) method simulating the metastatic evolu-
tion. In the “Results” section, we present the main
results of our study before and after treatment with the
monoclonal antibody. Except from the results of the
core group of patients, we also present some specific
cases which have non-tumour-related findings. Also we
present the results from the Kinetic Monte Carlo model
which involves propagation of malignant cells through a
fractal network causing occasional metastases and we
compare the numerical results to those of the analysis of
the PET/CT images. Finally, we recapitulate our main
results and discuss open problems.
Methods
Patients
The study involved 31 patients (P1, P2, …, P31) who suf-
fered from metastatic melanoma at various stages of the
disease. Each patient was scanned once before treatment
(study I, baseline scan) and in follow-up, during and
after treatment with the monoclonal antibody ipilimu-
mab. Follow-up scans were performed after two cycles
of ipilimumab treatment (study II, first follow-up scan),
and at the end of the four-cycle treatment (study III, sec-
ond follow-up scan). The time interval between the first
and the second scans was 5 weeks and the first and the
third scans 12 weeks after onset to therapy. Due to the
tendency of melanoma to produce metastases through-
out the body, whole-body scans were performed in all
three studies of each patient.
Patients gave written informed consent to participate
in the study and to have their medical records released.
The study was approved by the Ethical Committee of
the University of Heidelberg and the Federal Agency of
Radiation Protection.
Data acquisition
Whole-body PET/CT studies were performed from the
skull to the toes with an image duration of 2 min per
bed position for the emission scans. A dedicated PET/
CT system (Biograph mCT, S128, Siemens Co.,
Erlangen, Germany) with an axial field of view of
21.6 cm with TruePoint and TrueV, operated in a three-
dimensional mode was used. Spatial resolution is 4 mm
and the peak noise equivalent count rate (NECR) is
186 kcps at 30.1 kBq/mL [20]. A low-dose attenuation
CT (120 kV, 30 mA) was used for attenuation correc-
tion of the PET data and for image fusion. All PET
images were attenuation-corrected and an image matrix
of 400 × 400 pixels was used for iterative image recon-
struction. Iterative image reconstruction was based on
the ordered subset expectation maximization (OSEM)
algorithm with six iterations and 12 subsets. As was ex-
plained in the “Patients” section, for each patient Pi, i = 1,
…, 31, three whole-body scans were obtained: the baseline
scans and the two follow-up scans. Each one of these three
sequences comprises of about 400 images. The specifica-
tions of the PET images are given in Table 1.
It must be noted here that FDG also concentrates
physiologically in several healthy organs where meta-
bolic activity takes place. These organs are the heart,
the brain, the liver, the urinary tract (due to tracer ex-
traction) etc. Because it is not possible to systematically
differentiate between non-malignant enhanced FDG
activity (e.g. in inflammatory lesions) and abnormal ac-
tivity in the tumorous lesions, a systematic error is
introduced in the calculations of the fractal dimensions.
This systematic error will be discussed further in the
“Results” section.
Data analysis
Evaluation of the PET/CT data was performed using
dedicated software (Aycan Digitalsysteme, Würzburg,
Germany). Visual analysis was performed by two nu-
clear medicine physicians evaluating the hypermeta-
bolic areas on transaxial, coronal and sagittal images
which were considered to be malignant. Patient history
was studied thoroughly in order to exclude possible
causes of non-specific tracer accumulation and therefore
minimize false positive findings. The overall treatment
outcome was determined by the dermatooncologists and
included further parameters, like clinical data and radio-
logical imaging modalities.
Fractal and multifractal analysis
As discussed in the “Background”, melanoma is a fast
evolving tumour which expands forming numerous le-
sions throughout the body. To quantify the spatial
extension of the metastases, we use fractal analysis
which takes into account only the locations of the le-
sions, while multifractal analysis accounts also for the
size of the metastases in each affected area. The advan-
tage of using fractal analysis to address this problem is
that there exist a number of growth models/schemes
which give rise to fractal structures [21–27]. Depending
on the calculated fractal dimension, we can then point
to the appropriate mechanisms most accounting for the
spreading of the tumours.
From the many measures which are proposed for cal-
culating fractality of the spreading, we use here the most
classic one, the box-counting dimensions [2, 18, 19].
Table 1 General features of PET images
Specifications of PET images
Image size 400 × 400 pixels
Pixel size 2.03642 × 2.03642 mm2
Slice thickness 4 mm
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This measure has the advantage of being easy to imple-
ment and it gives directly a means of differentiating be-
tween homogeneous and hierarchical arrangement of
the lesions.
To implement the box-counting method, we divide
the 3D PET/CT image of the human body in cubic
boxes (3D pixels-voxels) of linear size s. The voxel linear
size was chosen considering the pixel size and the image
thickness (Table 1). According to the image specifica-
tions, the pixel size is approximately 2 mm × 2 mm and
the image thickness is 4 mm. To be consistent in the
three directions, we construct cubic boxes with a mini-
mum length of smin = 4 mm up to smax = 200 mm.
For each value of box size s, we calculate the number
of cubic boxes N(s) which contain tumour cells (primary
or metastatic). The presence of tumour cells in a given
position is recorded by the presence of the tracer. By
plotting N(s) as a function of s, we extract the fractal
dimension df fitting the data to the following formula:
N sð Þ ¼ Cs−df ð1Þ
where C is a constant, determined also by the above fit.
Alternatively, we can plot N(s) as a function of s in a
double logarithmic scale and the fractal dimension is
calculated as the slope of this curve.
In these calculations, a systematic error arises because
the tracer accumulates not only in malignant regions but
also in some healthy organs as well as in non-tumour-
related findings (e.g. inflammatory lesions). This error
tends to increase the fractal dimension towards the value
3, since the organs contribute substantial accumulations
of tracer in 3D volumes.
While fractal analysis uses only the presence of the tracer
in the particular lesion, multifractal analysis takes also into
account the concentration of the tracer which is accounted
for by the intensity pi of the colour in each voxel i. The
colour intensity is normalized so that
XN
i¼1
pi ¼ 1, in order
to get results which do not depend on the particular
average of the individual subjects, but only on the scal-
ing of their data. In this case, we use the smallest box
sizes available, because the multifractal spectrum requires
the finest details of the spatial structure. For the present
scans, the smallest box size available is (4 mm× 4 mm×
4 mm). The generalized dimensions Dq (or multifractal
spectrum) are calculated as follows:
Dq ¼ lim
s→0
1
q−1
1
ln s
ln
XN
i¼1
pqi
 !
; q≠1
D1 ¼ lim
s→0
1
ln s
X
i¼1
N
pi ln pi ; q ¼ 1
ð2Þ
where q is the dimension index which takes real values
(−∞, … , 0, … ,+∞), s = 4 mm, the index i runs over all
boxes and N is the total number of boxes of size (4 mm ×
4 mm× 4 mm) covering the body. Note that the nega-
tive values of q highlight the smallest values of pi (rare
events), while the larger positive values of pi are accentu-
ated by the positive values of q.
Finally, the integral difference of the multifractal
spectrum, average multifractal index DMF, between stud-
ies I and II (early), II and III (late) and I and III (final) is
useful, because it gives the tendency of the spectrum, av-
eraged over all q values. Formula 3 is used for the calcu-
lation of DMF between stages I and II,
DMF I;IIð Þ ¼ 12Lþ 1
XL
q¼−L
Dq Ið Þ−Dq IIð Þ
  ð3Þ
and similarly between stages II and III and between
stages I and III. In 3, L (−L) is the highest (lowest) order
of index q. When DMF takes positive values, the patient
improves, while for negative values his/her condition
deteriorates.
For the computations of the fractal dimensions, the
multifractal spectrum and the average multifractal index,
we use in-house software adjusted to the specific needs
of the PET/CT imaging data.
The Kinetic Monte Carlo method
Previous attempts to model the growth of tumours in-
clude both continuous and discrete approaches [28].
Most of these models deal with the growth of a single
lesion as a result of the increase of the number of ma-
lignant cells locally. The propagation of tumour cells
causing metastases has been studied using mainly con-
tinuous diffusion models [29–31]. In the current study,
we employ a stochastic microscopic approach, which
allows the malignant cells to move randomly through
the blood circulatory system [21–23]. To model the
metastatic process of melanoma, we allow a small num-
ber of malignant cells to diffuse through the blood cir-
culatory system and to cause occasional metastases in
the adjacent healthy tissue or organs.
More specifically, earlier studies have shown that the
blood circulatory system has a branching structure
whose geometry is fractal [3, 6]. As recapitulated in the
“Background”, the fractal dimensions recorded in the
literature is of the order of 2.6–2.7. The method of
Kinetic Monte Carlo (KMC) simulations for the spe-
cific application of the creation of metastatic lesions
consists in constructing the blood circulatory network
as a fractal medium, embedded in the 3D space repre-
senting the human body. The human body is then con-
structed as a 3D matrix consisting of (a) cells which
represent the fractal circulatory system, (b) cells which
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represent tissue and organs where metastasis can take
place and FDG is accumulated and (c) other unoccu-
pied (empty) areas. In this system, a small number (n)
of malignant cells are released to diffuse, while their
motion is restricted only within the areas covered by
the circulatory network, i.e. they do not enter the areas
outside the circulatory system [21, 24]. The motion of
the malignant cells is described as a classical random
walk (as assumed in this study) or a directed random
walk or an anomalous walk [25, 26]. Occasionally, with
very small probability (p) they invade the tissue (or or-
gans) adjacent to the circulatory system. The system is
integrated for a long time and as KMC time passes, the
number of tumour sites increases and they span more
and more areas around the body, all of them adjacent
to the circulatory system. In this way, a qualitative le-
sion distribution is obtained whose statistical charac-
teristics convey attributes similar to the ones recorded
from the medical images, provided the parameters of
the KMC model are representative of the evolution of
the disease.
To calculate the fractal dimensions of the KMC simu-
lation data, we use the same methods and in-house
software as for the medical data, i.e. we use the box-
counting algorithm described in the “Fractal and multi-
fractal analysis” section to calculate the df from the
simulations, for direct comparison with the results
from the PET/CT images.
Results
Typical patients
For each patient, we calculated the box-counting
dimensions according to Formula 1, before medical
treatment (study I), after two cycles of ipilimumab
treatment (study II) and at the end of the four-cycle
treatment (study III). The results for all subjects are
given in Table 2. First, the results of the 31 patients are
recorded, followed by the 2 healthy subjects.
The general analysis and comparison between the
fractal dimensions before and after treatment shows
that the tracer has the tendency to spread in higher
dimensionality in healthy subjects and also when the
treatment is successful. Typical healthy subjects dem-
onstrate fractal dimensions (in physiological distribu-
tion of tracer) around 2.7 (see healthy subjects 1 and 2,
at the end of Table 2). Since the tracer is not accumu-
lated by malignant lesions in healthy subjects, it tends
to spread almost homogeneously throughout the 3D
extension of the body, or concentrates in the 3D vol-
ume covered by organs in which biochemical activity
takes place. In these cases, the spreading is expected to
show fractal dimensions almost equal (very close) to 3.
The results from the PET/CT images of healthy sub-
jects show smaller fractal dimensions because of the
different tracer distribution in the organs, including
some organs like the liver and brain that physiologically
accumulate FDG. Both these factors lower, in the statis-
tical sense, the fractal dimensions in healthy subjects
below 3.
When lesions are spreading through the body, the
tracer starts to accumulate in areas where the metastases
are active. If we make the assumption that the spreading
takes place through the blood circulatory network and
that the metastases are engendered around it, we expect
that the spreading at the beginning will start having
small extension (thus small fractal dimensions) while at
later stages the lesions’ spatial extension will increase,
approaching at most the spatial extension (and thus the
fractal dimensions) of the circulatory network. (Correc-
tions to these calculated values must be taken into
account due to the tracer accumulation by healthy or-
gans). These propositions are in agreement with the
findings, using the patients’ treatment outcome as refer-
ence, that (a) when the treatment with ipilimumab leads
to improvement of therapy outcome the fractal dimen-
sion increases as the patient improves, (b) when the
patient’s condition is stable, df does not change drastic-
ally and (c) when the patient’s condition deteriorates df
takes smaller values because the tracer concentrates fur-
ther in the active lesions rather than in normal organs.
A representative plot for patient P3 is shown in Fig. 1.
With the red line, we represent the analysis of study I,
when the metastatic melanoma was diagnosed, with the
blue line is the analysis after two cycles of ipilimumab
treatment (study II) and with the green line the analysis
after four cycles of treatment (study III). As indicated by
the treatment outcome, the patient at the baseline study
I showed low fractal dimensions df(I) = 2.46 (metastatic
invasion). After two cycles, we have an improvement of
the patient’s condition and df(II) increased to 2.64, and
after four cycles, df(III) did not change substantially,
showing a stable phase of the disease. In the same figure,
the line corresponding to the analysis of the Healthy
Subject (2) is plotted, for comparison.
The results of the multifractal spectrum verify further
the fractal analysis. For the same patient, the generalized
dimensions are presented in Fig. 2. Again, the red line
which corresponds to the initial diagnosis of the disease
(study I) is lower than all other lines. The blue line
which records the analysis after two cycles of treatment
(study II) and the green line, after four cycles (study III),
are at the same level, higher than the baseline spectrum.
This indicates improvement in the patient conditions
and elimination of malignant lesions. Again, the black
line which denotes the multifractal spectrum of the
healthy subject is plotted in Fig. 2, for comparison.
Another representative plot from patient P12, whose con-
dition according to the treatment outcomes deteriorates
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Table 2 Analysis results for all patients
Patient no. Age (years) Sex (M/F) Study Treatment response Fractal dimension Average multifractal index Matching results
P1 67 M Early a 2.487 −0.064 Typ
Late a 2.509 −0.030
Final PR 2.525 −0.095
P2 48 F Early PD (slow) 2.611 +0.043 Typ
Late MR 2.588 −0.029
Final MR 2.623 +0.013
P3 56 M Early a 2.465 −0.119 Typ
Late a 2.644 −0.015
Final PR 2.643 −0.135
P4 62 M Early PD 2.688 −0.108 Typ
Late MR 2.743 +0.003
Final PD 2.726 −0.104
P5 37 F Early PD (slow) 2.512 +0.181 Typ
Late PD (slow) 2.395 −0.308
Final PD (slow) 2.602 −0.127
P6 55 M Early PD 2.634 −0.024 Typ
Late PD 2.673 +0.174
Final PD 2.511 +0.150
P7 55 M Early PD 2.65 +0.077 Typ
Late SD 2.629 −0.024
Final PD 2.624 +0.053
P8 74 M Early PD (slow) 2.622 +0.01 Typ
Late SD 2.629 +0.11
Final PD 2.529 +0.13
P9 60 F Early PD 2.618 +0.016 Non-Typ+
Late PD 2.603 −0.14
Final PD 2.655 −0.124
P10 67 M Early SD 2.589 −0.065 Non-Typ
Late PD 2.633 −0.044
Final PD 2.652 −0.11
P11 56 M Early MR 2.453 −0.369 Typ
Late PD (slow) 2.719 +0.455
Final MR 2.4 +0.085
P12 55 M Early PD (slow) 2.637 +0.044 Typ
Late PD 2.591 +0.03
Final PD 2.56 +0.075
P13 71 M Early SD 2.653 −0.113 Typ
Late SD 2.676 +0.07
Final PR 2.683 −0.043
P14 36 M Early PD 2.616 +0.053 Typ
Late PD 2.613 +0.106
Final PD 2.523 +0.159
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Table 2 Analysis results for all patients (Continued)
P15 55 M Early SD 2.593 −0.264 Non-Typ+
Late SD 2.707 +0.281
Final SD 2.575 0.017
P16 73 M Early SD 2.61 −0.075 Typ
Late PD (slow) 2.676 +0.063
Final PD (slow) 2.618 −0.012
P17 61 F Early PD (slow) 2.698 +0.001 Typ
Late PR 2.697 −0.033
Final PR 2.705 −0.031
P18 71 M Early PD 2.697 −0.031 Non-Typ+
Late PD 2.684 −0.047
Final PD 2.713 −0.078
P19 39 M Early PD (slow) 2.611 −0.036 Typ
Late SD 2.629 +0.088
Final PD (slow) 2.572 +0.052
P20 70 M Early PD 2.663 +0.045 Typ
Late PD 2.659 −0.021
Final PD 2.621 +0.024
P21 49 M Early MR 2.533 +0.012 Non-Typ
Late PD 2.518 −0.036
Final PD 2.556 −0.023
P22 66 M Early SD 2.572 −0.037 Typ
Late SD 2.561 +0.031
Final SD 2.582 −0.005
P23 75 M Early PR 2.68 +0.09 Non-Typ+
Late PD 2.609 +0.011
Final PD 2.651 +0.101
P24 67 M Early SD 2.687 +0.03 Non-Typ+
Late PD (slow) 2.67 −0.071
Final PD (slow) 2.741 −0.04
P25 65 F Early MR 2.48 −0.319 Typ
Late MR 2.699 +0.151
Final MR 2.614 −0.168
P26 73 F Early PR 2.65 −0.081 Non-Typ
Late PD 2.708 −0.07
Final PD 2.714 −0.151
P27 62 M Early PD 2.602 +0.021 Non-Typ+
Late PR 2.599 +0.047
Final PR 2.576 +0.069
P28 54 F Early PR 2.699 +0.129 Typ
Late PR 2.655 −0.187
Final PR 2.716 −0.058
P29 61 F Early PR 2.622 −0.019 Non-Typ
Late PR 2.632 −0.032
Final PR 2.651 −0.052
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during therapy, is shown in Fig. 3. In this case, the df value
drops successively among the different studies. On study I,
the fractal dimension showed the highest value df(I) = 2.63.
As the disease progressed, a decrease in df values is
shown with df(II) = 2.59 and df(III) = 2.56. The above
confirms the hypothesis that in the presence of developing
malignant lesions the tracer tends to accumulate in them,
showing hierarchical expansion of low dimensionality. Fig-
ure 4 presents the multifractal spectrum for the same pa-
tient. The curve shapes corroborate the results of the
fractal analysis showing a similar decreasing tendency.
Comparatively, all the results for all patients are
recorded on Table 2. In the first column, the patient
index is given, as P1, P2, …, P31. In the second and third
columns, the patient’s age and sex are recorded. In the
fourth column, the three therapy stages are set, while in
the fifth column the treatment outcomes are reported
based on clinically used criteria for therapy response
evaluation. We characterize the progression of the dis-
ease between studies I and II (Early), studies II and III
(Late) and studies I and III (Final), according to treat-
ment outcome as defined by the referring oncologists.
The patient’s condition is characterized by the oncolo-
gists as partial remission (PR) if the patient improves
after treatment, as stable disease (SD) if the patient’s
condition is stable, as progressive disease (PD) if the pa-
tient deteriorates and as mixed response (MR) in case of
good response in some lesions and non-response in
Table 2 Analysis results for all patients (Continued)
P30 53 M Early SD 2.544 +0.051 Typ
Late SD 2.534 −0.203
Final SD 2.676 −0.152
P31 78 F Early SD 2.588 +0.046 Non-Typ+
Late SD 2.554 −0.165
Final SD 2.633 −0.118
Healthy subject 1 69 F – – 2.69 – –
Healthy subject 2 73 M – – 2.723 – –
Early stage: study I→ study II; late stage: study II→ study III; final stage: study I→ study III
Typ: correspondence between analysis results and treatment outcome data
Non-Typ: non-typical patient (unknown reasons)
Non-Typ+: non-typical patient due to unspecific findings
PR partial remission, SD stable disease, PD progressive disease, MR mixed response
aNo treatment outcome data
Fig. 1 The number of boxes N(s) as a function of the box size s for patient P3. His/her condition improves after medical treatment with
ipilimumab. The solid lines represent the linear regressions to the data
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others. We used the term of MR to describe the non-
uniform response to treatment, which is often the case
due to tumour heterogeneity. The sixth column records
the fractal dimension characteristic of the particular study.
In the seventh column, the early, late and final average
multifractal indices are reported, using Formula 3. In the
last column, the patient is characterized as standard/
typical (Typ) if he/she only suffers from metastatic melan-
oma and the comparison of the analysis results and the
treatment outcome results follow the typical pattern as ex-
plained in the “Typical patients” section.
The patient is characterized as non-typical + (Non-
Typ+) if he/she has a non-tumour-related finding or as
non-typical (Non-Typ) if the results of the fractal
Fig. 2 The generalized dimensions Dq as a function of the index q for patient P3. The patient’s condition improves after medical treatment
with ipilimumab
Fig. 3 The number of boxes N(s) as a function of the box size s for patient P12. His/her condition deteriorates during medical treatment with
ipilimumab. The solid lines represent the linear regressions to the data
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analysis were not consistent with the treatment outcome
data for unknown reasons. Patients characterized as
Non-Typ+ are individually discussed in the next section.
Unspecific tracer uptake not related to melanoma disease
In this section, we present two cases of non-typical pa-
tients, both with medical findings not directly related to
the melanoma disease. In both cases, there is an uptake
of FDG in non-tumorous areas and thus the results of
the fractal/multifractal analysis are incompatible with
the treatment outcome data.
The case of colitis
Patient P15 who suffers from metastatic melanoma pre-
sents one metastatic lesion in the sixth thoracic verte-
bra, which is clearly delineated in the maximum
intensity projection images in both follow-up studies
(see Fig. 5). The same patient suffers also from fast
evolving colitis, which is a side-effect of ipilimumab
therapy and this is evident from the high uptake of
FDG in the colon as shown on study III. Furthermore,
there is tracer retention in both ureters in the third
study, which is also a finding not related to the melan-
oma disease. Thus the distribution of FDG is divided
between healthy organs, metastatic lesions and the
colon area. This introduces a large error in the calcula-
tions, and as a result, the fractal dimension increases in
the study II and decreases in the study III, while the pa-
tient’s condition remains practically steady.
The case of unspecific FDG uptake (thrombophlebitis)
Patient P31 in the stage of treatment (study II) presents
an increase in FDG uptake in the left leg which disap-
pears in the study III. This uptake is not related to fast
progressing melanoma but to an inflammatory vessel
disease (see Fig. 6). Due to this higher dispersion of the
FDG biomarker, the fractal dimension decreases in study
II, as if the patient was deteriorating (developing further
lesions) while the treatment outcome data indicate that
the patient’s condition is stable. Similar, hypermetabolic
lesions not directly related to melanoma (unspecific
findings) altering the results of the fractal/multifractal
analysis are met in 7 out of 31 patients. These patients
are marked as Non-Typ+ in Table 2.
The results of this section demonstrate that the frac-
tal/multifractal analysis predicts correctly the evolution
of metastatic melanoma in 83.3 % (20 in 24) of the
cases, giving results compatible with the treatment out-
come data. In 7 cases, combined effects of melanoma
and other non-specific findings (e.g. inflammatory le-
sions) give results non-compatible with treatment out-
come data. We stress again that the fractal/multifractal
analysis of the metastatic melanoma spreading must be
always complemented with medical assessment in order
to exclude regions with false positive FDG uptake not
related to the disease.
Kinetic Monte Carlo simulations
For this study, the blood circulatory network was con-
structed as a deterministic fractal embedded in 3D space
Fig. 4 The generalized dimensions Dq as a function of the index q for patient P12. The patient’s condition deteriorates during medical treatment
with ipilimumab
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Fig. 6 PET/CT images of patient P31 at the three stages. The patient presents high unusual uptake of the FDG biomarker in his/her left leg at the
second stage of treatment, not related to the melanoma
Fig. 5 PET/CT images of patient P15 suffering from colitis. The patient presents high uptake of the FDG biomarker not only due to the melanoma
metastases but also due to the presence of colitis, not related to the melanoma
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representing the human body. The system (body) size
was L × L × L = 81 × 81 × 81 sites (3D representation),
and the deterministic fractal network corresponding to
the circulatory system was constructed iteratively within
this 3D space. The fractal network spans the body and
its fractal dimension df was chosen df
c = ln(18)/ln(3) =
2.69 to be similar to the value reported in the literature.
Once the positions of the sites belonging to the circula-
tory system were assigned, a small number (n = 10) of
malignant cells were released to diffuse only within the
areas covered by the circulatory network. Occasionally,
with very small probability (p), they infect the tissue (or
organs) adjacent to the circulatory system. As time
passes, the number of tumour lesions increases and
they span more and more areas around the body, all of
them adjacent to the circulatory system.
To find the characteristics of the spatial distribution of
the metastatic lesions produced by the KMC model, we
use the same algorithm (box-counting method) as in the
calculations of the fractal dimensions of the PET/CT im-
ages, i.e. we divide the 81 × 81 × 81 sites in cubic boxes
of size s = 1, 2, …, 20, and we calculate the number of
boxes N(s) which contain at least one infected site. In a
double logarithmic scale, the tangent of the number of
boxes N(s) versus the box size s expresses the fractal di-
mensions df(sim). The results of a typical simulation are
shown in Fig. 7. In this simulation, each malignant cell
diffuses for time T = 100 × L3 where L is the linear size
of the body (in voxels). At every elementary time step,
they diffuse randomly into nearest neighbouring sites
(provided that they belong to the circulatory system),
and with probability p = 0.001, they cause metastases in
the nearby tissues or organs.
The number of metastatic regions at this time shows a
typical power law with exponent df(sim) = 2.76, close to
the one of the circulatory system. In earlier times, the
metastases distribution is more sparse and the evolution
of the fractal dimension with time is shown on Fig. 8.
This figure shows that as time increases the fractal
dimension of the metastatic lesions approaches closely
the one of the circulatory system. In fact, it tends to be a
little higher. This is explained because the lesions are lo-
cated all around the blood network covering a larger
area than the network itself. Consequently, the corre-
sponding fractal dimension tends to be slightly higher, in
the limit of large times. We believe that the recorded
PET/CT scans represent earlier, transient times before
the malignant cells have the time to invade all the max-
imum body “volume” around the circulatory system.
Fractal laws have been also demonstrated in the time
activity curve of FDG in different tumours [32]. A simi-
lar tendency is demonstrated by the number of meta-
static sites Nm as a function of time shown in Fig. 9.
Nm increases at the beginning while after the transient
it approaches a constant value, since most regions
around the circulatory system have been infected and
secondary infection of the same site is not allowed in
the simulations. In the same figure, the simulation re-
sults are approximated using a nonlinear curve fit of
the type [24]:
Nm tð Þ ¼ Atα exp −βtð Þ ð4Þ
This formula takes into account the power law (fractal)
nature of the problem, expressed by the exponent α and
the levelling up of the curve which is attained by the
Fig. 7 The number of boxes containing metastases as a function of the box size s. The linear system size is L = 81, the probability of infection is
p = 0.001, the infecting seeds are n = 10 and the time of the simulation is T = 100 × L3
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exponential decay term exp(−βt). The nonlinear curve fit
gives parameter values α = 0.808 and β = −0.0045, with
correlation coefficient 0.999697. The number of in-
fected/malignant sites Nm cannot be directly correlated
with the number of observed metastatic lesions in the
PET/CT images. Each metastatic site may expand in-
creasing the size of the lesion, but this feature has not
been considered in the present version of the KMC
model.
The minimal KMC model is a mechanistic scheme for
the spreading of metastases in the human body. It ac-
counts for the fractal spreading as calculated from the
PET/CT images and has a similar fractal dimension.
This model needs to be further explored in order to
account for more precise metastasis characteristics. Ex-
tensions and improvements to the KMC model are dis-
cussed in the “Open problems and limitations” section.
Discussion
In this section, we first present the main results of the
PET/CT fractal analysis in the “Fractal and multifractal
properties of the PET/CT images” section followed by
the results produced by the KMC model in the “Kinetic
Monte Carlo simulations and results” section, for com-
parison. The limitations of these approaches and algo-
rithms are discussed in the “Open problems and
limitations” section.
Fig. 8 The temporal evolution of df(sim)
Fig. 9 Evolution of the number of metastatic sites with time. The crosses represent the simulation results and the red dashed line the nonlinear
curve fit
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Fractal and multifractal properties of the PET/CT images
We have used the methods of fractal and multifractal
analysis to quantify the spatial extension of the malig-
nant lesions in patients with metastatic melanoma, be-
fore and after treatment with ipilimumab. We analysed
the PET/CT data from 31 patients prior, early in the
course of treatment and immediately after the end of the
treatment. The fractal dimensions show low, decreasing
values in patients with progressive disease, demonstrat-
ing the tendency of the tracer to concentrate in the
sub-region of the body where metabolic activity takes
place. However, in cases of successful medical treat-
ment, the lesions cease to attract the tracer and the
fractal dimensions increase, showing the tendency of
the tracer to diffuse in all parts of the body. In 20 out
of 24 cases (83.3 %), the results of the fractal and multi-
fractal analysis were consistent with the treatment out-
come data. For the remaining seven patients, non-
tumour-related medical conditions led to abnormal
tracer uptake, which gave false quantitative results.
Two of these cases were demonstrated in detail in the
“Unspecific tracer uptake not related to melanoma dis-
ease” section as common atypical cases.
Kinetic Monte Carlo simulations and results
To understand the quantitative results, we have devised
the stochastic KMC model, based on the random drift of
malignant cells through the blood circulatory system,
which colonize randomly the surrounding tissue. The
main results of the KMC model is that as the malignant
cells diffuse through the blood network colonizing at
first contact (with given, small probability), the colonies
at the beginning of the process seem to be scattered ran-
domly in the body. As time evolves, and more and more
metastases occur, the metastatic topology will develop
following the shape of the accommodating blood circula-
tory (or other hosting) network. This is clearly shown in
the time evolution of the fractal dimensions, which as
time evolves approach the limiting set with df = 2.7,
characteristic of biological networks. The spatial distri-
butions of metastases produced by the KMC model are
statistically similar to the ones observed in melanoma
patients.
The number of malignant sites in the KMC model is
shown to follow a mixed mathematical increasing ex-
pression containing both exponential and power law
parts, characteristic of fractal growth phenomena [27].
This mathematical formula can be used as predictor for
the extension of the “volume” of the metastatic lesions
with time, provided that more frequent scans of the
patients are available in order to have enough data to
accurately fix the values of the constants A, α and β in
Formula 4.
Open problems and limitations
One limitation of the present study is the selectivity of
the algorithm used for the calculation of the fractal and
multifractal dimensions. An important improvement to
the algorithm would be the ability to exclude healthy or-
gans where the tracer physiologically accumulates, as
well as areas which show an unspecific non-tumour-
related FDG uptake. This became evident during the
data evaluation and after the comparison between the
results of the fractal analysis and the treatment outcome
data. It is possible to overcome this problem either with
the development of new, smart algorithms able to mask
areas with non-tumour-related tracer uptake, or by using
a specific tracer, which does not show accumulation in
inflammatory areas. Other nonlinear measures such as
the spatial correlations, higher order moments of the
spatial distribution and clustering coefficients can be
used to characterize the metastatic potential of the tu-
mours and can improve the predictions of therapy out-
come. These measures can be easily incorporated in the
existing algorithms.
The results of the changes on df and Dq presented in
Table 2 are suggestive of the evolution of melanoma, but
it would be useful to establish the ranges of these mea-
sures in the healthy subjects and patients with different
tumorous stages. Because melanoma is a disease which
evolves fast (and so does df and Dq), it would be useful
to clinically classify various stages of melanoma and spe-
cify the ranges of df and Dq associated with each stage,
including the healthy stage. Even with a limited number
of subjects, the use of random resampling statistical
methods allows to safely determine the df and Dq confi-
dence intervals, provided that the subjects are properly
classified at the various stages of the disease [33–36].
A direct improvement to the KMC model would be to
choose a spatial extension similar to the one used in
PET/CT (e.g. 400 × 400 × 400 depending on the patient
height) rather than the simple cubic (81 × 81 × 81) used
here. Instead of using a deterministic fractal, we could
mimic the circulatory network itself, drawing from med-
ical images. We can also vary the number of malignant
cells which circulate in the blood vessels and make their
motion more realistic, rather than classical diffusion. It
is also possible to arrange the malignant cells to start
from a single tumorous area (e.g. the primary tumour)
rather than spreading them randomly in the circulatory
network. These additions to the KMC model could lead
to even closer predictions of the spatial distribution of
the lesions in metastatic melanoma.
Conclusions
In this study we present a new method based on the
calculations of fractal and multifractal dimensions of
PET/CT images with FDG tracer for monitoring of the
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therapeutic effect of ipilimumab in patients with meta-
static melanoma. The results show enough evidence
that the fractal and multifractal analyses have the po-
tential to serve as biomarkers, for therapy monitoring
and for following the evolution of metastases in the
body. This is a robust, operator-independent method
which is based on static images, can be easily imple-
mented and demonstrated a correct classification rate
of 83.3 % in this study. It can be used as an additional
quantitative parameter for the assessment of the thera-
peutic outcome in clinical routine in particular within a
multiparameter evaluation approach [13]. Additional
studies over a larger number of patients are needed to
verify the impact of this method, as well as refinement
of the developed algorithms to improve their predictive
value.
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